Search company, investor...


Founded Year



Incubator/Accelerator | Alive

About BioSignals

BioSignals has developed VR learning courses that use biological sensors, mobile technology, and personal trainers to teach people how to handle stress, improve their performance, and improve their health.

Headquarters Location

Unit 1, 1/F Mau Lam Comm Bldg 16-18 Mau Lam Street


Hong Kong


Missing: BioSignals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: BioSignals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing BioSignals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BioSignals is included in 3 Expert Collections, including AR/VR.



1,376 items

This collection includes companies creating hardware and/or software for augmented reality, virtual reality, and mixed reality applications.


Digital Health

13,579 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)


Mental Health Tech

1,271 items

This collection includes companies applying technology to problems of emotional, psychological, and social well-being. Examples include companies working in areas such as substance abuse, eating disorders, stress reduction, depression, PTSD, and anxiety.

Latest BioSignals News

Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership

Jul 9, 2021

Beacon Biosignals and Cyclerion to extend and expand partnership on data collection and analytics strategy to facilitate development of Cyclerion investigational therapeutics for neurological diseases associated with cognitive impairment News provided by Share this article Share this article BOSTON, July 8, 2021 /PRNewswire/ -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN ) and Beacon Biosignals today announced an extended and expanded strategic partnership between the two companies. This collaboration is expected to identify disease-relevant biomarkers to refine patient selection and endpoints to guide the clinical development of Cyclerion's investigational therapeutics for neurological diseases associated with cognitive impairment. Beacon Biosignals' EEG neurobiomarker platform is engineered to discover and scale new clinical paradigms for patients with neurological and psychiatric disease. Beacon Biosignals brings a world-class clinical electroencephalogram (EEG) database coupled with proprietary, artificial intelligence-based algorithms and analytical capabilities to identify neurological biomarkers of drug action and efficacy. Distinct EEG profiles are associated with neurodevelopmental status and various neurological diseases, and can be affected by neurologically active therapeutics. The platform rapidly characterizes these effects and guides dose selection in humans to help overcome the challenges of translating PK/PD models from preclinical animal studies. Beacon Biosignals and Cyclerion previously collaborated on the analysis of data from a Cyclerion clinical translational pharmacology study of CY6463 which demonstrated clear effects on EEG parameters associated with aging and disease. These data were recently presented at the annual meeting of the American Academy of Neurology (Glasser et al., 2021). Incorporation of the Beacon Biosignals approach in ongoing and planned Cyclerion patient studies is expected to support the continued clinical development of CY6463, the Company's lead clinical program, as well as CY3018, a next-generation preclinical program. CY6463 is an oral, first-in-class, central nervous system (CNS)-penetrant sGC stimulator that is being developed for neurological diseases associated with cognitive impairment. CY6463 was designed to address multiple pathophysiological features of neurodegenerative and neuropsychiatric diseases associated with cognitive impairment. Results from initial CY6463 clinical studies have demonstrated favorable safety and tolerability and pharmacologically relevant drug exposure in the cerebral spinal fluid. In addition, CY6463 resulted in promising impacts on EEG measures, neuroinflammation, and other neurophysiological measures that support continued clinical development. Patient studies to further evaluate CY6463 safety and signals of clinical activity in studies in Alzheimer's disease with vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) are ongoing, and a study in individuals with Cognitive Impairment Associated with Schizophrenia (CIAS) is expected to initiate shortly. Analysis of EEG and other neurological biomarkers will be an important aspect of these studies. "Beacon Biosignals is the leader in the identification of disease-relevant EEG neurological biomarkers. We believe that the application of this technology to our innovative pipeline may be quite powerful in guiding efficient drug development, and we look forward to a productive partnership focused on successfully advancing CY6463 for diseases associated with cognitive impairment," said Andy Busch Ph.D., Chief Scientific Officer of Cyclerion Therapeutics. "We are eager to apply our proprietary AI-based analytical capabilities to support the development of Cyclerion's promising therapeutic candidates. We believe that our platform has the capacity to identify novel disease-relevant biomarkers that may help guide patient selection or endpoint identification for future clinical development," said Jacob Donoghue, M.D., Ph.D., Chief Executive Officer of Beacon Biosignals. About Cyclerion Therapeutics  Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion is advancing novel, first-in-class, CNS-penetrant, sGC stimulators that modulate a key node in a fundamental CNS signaling pathway. The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases. The most advanced compound, CY6463, has shown rapid improvement in biomarkers associated with cognitive function and is currently in clinical development for Alzheimer's Disease with Vascular pathology (ADv), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS), and Cognitive Impairment Associated with Schizophrenia (CIAS). Cyclerion is also advancing CY3018, a next-generation sGC stimulator. For more information about Cyclerion, please visit  and follow us on Twitter (@Cyclerion) and LinkedIn ( ). About Beacon Biosignals Beacon's machine learning platform for EEG enables and accelerates new treatments that transform the lives of patients with neurological and psychiatric disease. Through novel machine learning algorithms, enormous datasets, and advances in software engineering, Beacon Biosignals is changing the way patients are treated for disorders of the brain. For more information about Beacon Biosignals, please visit and follow us on Twitter (@biosignals) and LinkedIn ( ). Forward Looking Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties. We may, in some cases use terms such as "predicts," "believes," "potential," "continue," "anticipates," "estimates," "expects," "plans," "intends," "may," "could," "might," "likely," "will," "should" or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks listed under the heading "Risk Factors" and elsewhere in Cyclerion's 2020 Form 10-K filed on February 25, 2021, and subsequent SEC filings including the Form 10-Q filed on April 30, 2021. Investors are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and Cyclerion undertakes no obligation to update these forward-looking statements, except as required by law. Cyclerion Investors

BioSignals Frequently Asked Questions (FAQ)

  • When was BioSignals founded?

    BioSignals was founded in 2017.

  • Where is BioSignals's headquarters?

    BioSignals's headquarters is located at Unit 1, 1/F Mau Lam Comm Bldg, Kowloon.

  • What is BioSignals's latest funding round?

    BioSignals's latest funding round is Incubator/Accelerator.

  • Who are the investors of BioSignals?

    Investors of BioSignals include MindCET.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.